close 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Investeringen brengen risico`s met zich mee en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Aandelen Lijst・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Gesloten

SectorGezondheidszorg

8.57 -0.46

Strong Buy

Prijsupdate 17 apr 2026, 19:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.42

Max

8.61

Belangrijke statistieken

By Trading Economics

Inkomsten

-69M

-102M

Verkoop

-10M

34M

EPS

-5.69

Winstmarge

-299.886

Werknemers

228

EBITDA

4.7M

-18M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+74.22% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

30M

187M

Vorige openingsprijs

9.03

Vorige sluitingsprijs

8.57

Nieuwssentiment

By Acuity

50%

50%

168 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.9501 / 7.66 Steun & Weerstand

Karyopharm Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 apr 2026, 20:26 UTC

Acquisities, Fusies, Overnames

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

DJ

Lezen

17 apr 2026, 18:15 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

DJ

Lezen

17 apr 2026, 16:49 UTC

Belangrijke Nieuwsgebeurtenissen

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

DJ

Lezen

17 apr 2026, 16:49 UTC

Belangrijke Nieuwsgebeurtenissen

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

DJ

Lezen

17 apr 2026, 22:58 UTC

Winsten

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

DJ

Lezen

17 apr 2026, 21:32 UTC

Marktinformatie

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

DJ

Lezen

17 apr 2026, 21:22 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

17 apr 2026, 21:22 UTC

Marktinformatie

Moody's Downgrades Belgium to A1 -- Market Talk

DJ

Lezen

17 apr 2026, 20:52 UTC

Winsten

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

DJ

Lezen

17 apr 2026, 20:50 UTC

Marktinformatie
Winsten
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

DJ

Lezen

17 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

17 apr 2026, 20:29 UTC

Winsten

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

DJ

Lezen

17 apr 2026, 20:11 UTC

Acquisities, Fusies, Overnames

UCB to Buy Neurona Therapeutics for Up to $1.15B

DJ

Lezen

17 apr 2026, 19:34 UTC

Marktinformatie
Winsten
Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

DJ

Lezen

17 apr 2026, 19:34 UTC

Marktinformatie
Winsten
Acquisities, Fusies, Overnames

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

DJ

Lezen

17 apr 2026, 19:31 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

DJ

Lezen

17 apr 2026, 19:26 UTC

Marktinformatie

U.S. Natural Gas Futures Edge Up -- Market Talk

DJ

Lezen

17 apr 2026, 19:21 UTC

Marktinformatie

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

DJ

Lezen

17 apr 2026, 19:15 UTC

Marktinformatie

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

DJ

Lezen

17 apr 2026, 19:07 UTC

Marktinformatie

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

DJ

Lezen

17 apr 2026, 18:57 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

DJ

Lezen

17 apr 2026, 18:53 UTC

Acquisities, Fusies, Overnames

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

DJ

Lezen

17 apr 2026, 18:53 UTC

Acquisities, Fusies, Overnames

UCB 2026 Rev Guidance Unchanged

DJ

Lezen

17 apr 2026, 18:52 UTC

Acquisities, Fusies, Overnames

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

DJ

Lezen

17 apr 2026, 18:52 UTC

Acquisities, Fusies, Overnames

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

DJ

Lezen

17 apr 2026, 18:14 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

DJ

Lezen

17 apr 2026, 18:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

DJ

Lezen

17 apr 2026, 18:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

DJ

Lezen

17 apr 2026, 17:31 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

DJ

Lezen

17 apr 2026, 17:26 UTC

Marktinformatie
Winsten

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

Karyopharm Therapeutics Inc Prognose

Koersdoel

By TipRanks

74.22% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 15 USD  74.22%

Hoogste 28 USD

Laagste 8 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Karyopharm Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Karyopharm Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.9501 / 7.66Steun & Weerstand

Korte Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Strong Bearish Evidence

All events are bearish.

Lange Termijn

No Evidence

There are no events.

Sentiment

By Acuity

168 / 348 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

MDT

Medtronic PLC

86.08

↑ +0.56%

A

Agilent Technologies Inc

121.65

↑ +2.99%

VEEV

Veeva Systems Inc

167.9

↑ +0.35%

HQY

HealthEquity Inc

85.93

↑ +1.81%

NEOG

Neogen Corp

9.5

↑ +2.81%
help-icon Live chat